SAN FRANCISCO, August 12, 2025 – Inc., the leading media brand and playbook for the entrepreneurs and business leaders shaping our future, today announced that SamaCare, a cloud-based patient access platform for specialty medications, is No. 578 on the annual Inc. 5000 list, the most prestigious ranking of the fastest-growing private companies in America.

“SamaCare’s growth is directly tied to real human impact — and that’s what truly motivates us,” said Syam Palakurthy, founder and CEO of SamaCare. “SamaCare helps remove the administrative barriers that prevent patients from accessing life-saving therapies. We’re proud to work alongside passionate healthcare providers and pharmaceutical partners who share our commitment to improving and extending lives.”

Among healthcare and medical services companies, SamaCare ranks No. 68, while SamaCare ranks No. 94 in the state of California – home to some of the world’s largest private companies.

“It’s remarkable to see SamaCare reach the #94 spot in California’s Inc. 5000 rankings — a state that’s home to some of the world’s most innovative and well-funded private companies,” said Bradley Sloan, Managing Partner, Questa Capital. “Equally impressive is their #68 ranking in the healthcare services category, competing alongside massive incumbents. SamaCare’s success isn’t just their own — it benefits the entire healthcare ecosystem. When patients get on prescribed therapies without unnecessary delay, we all win.”

SamaCare is a cloud‑based Script‑to‑Therapy Operating System™ that streamlines the specialty drug prior authorization, enrollment, and benefit verification process for medical practices. SamaCare’s platform not only combines AI with expert human support to resolve more than 1 million prior authorizations across a network of over 20,000 providers and clinics, but also it generates insights into often opaque barriers hindering therapy uptake—insights that aren’t available elsewhere.

SamaCare’s platform enables pharmaceutical market access teams to diagnose why patients aren’t starting prescribed therapies, deploy targeted intervention campaigns across its provider network, educate clinicians, and measure the outcomes of those efforts. This deeper visibility empowers pharma stakeholders—who invest billions in developing and marketing new therapies—to close a critical blind spot in treatment access and ultimately improve patient care.

“Making the Inc. 5000 is always a remarkable achievement, but earning a spot this year speaks volumes about a company’s tenacity and clarity of vision,” says Mike Hofman, editor-in-chief of Inc. “These businesses have thrived amid rising costs, shifting global dynamics, and constant change. They didn’t just weather the storm—they grew through it, and their stories are a powerful reminder that the entrepreneurial spirit is the engine of the U.S. economy.”

For the full list, company profiles, and a searchable database by industry and location, visit: www.inc.com/inc5000.

Methodology

Companies on the 2025 Inc. 5000 are ranked according to percentage revenue growth from 2021 to 2024. To qualify, companies must have been founded and generating revenue by March 31, 2021. They must be U.S.-based, privately held, for-profit, and independent—not subsidiaries or divisions of other companies—as of December 31, 2024. (Since then, some on the list may have gone public or been acquired.) The minimum revenue required for 2021 is $100,000; the minimum for 2024 is $2 million. As always, Inc. reserves the right to decline applicants for subjective reasons.